1337482-15-1

Usage

Uses

Used in Pharmaceutical Industry:
Sofosbuvir IMpurity C 1337482-15-1 is used as an impurity in the development and manufacturing process of PSI-7977 (P839640), a prodrug for the treatment of hepatitis C. Its presence is crucial for the ongoing research and clinical trials to ensure the safety, efficacy, and quality control of the drug.
Additionally, as part of the drug development process, understanding the properties and effects of Sofosbuvir IMpurity C 1337482-15-1 can contribute to the optimization of the active pharmaceutical ingredient (API) and the overall drug formulation. This may lead to improved treatment outcomes and reduced side effects for patients suffering from hepatitis C.

Upstream product

• 863329-66-2 2'-deoxy-2'-fluoro-2'-methyluridine 
• 1334513-02-8 (S)-2-[(S)-((2,3,4,5,6-pentafluorophenoxy)(phenoxy)phosphoryl)amino]propionic acid isopropyl ester 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 1627824-09-2 (R)-2-((R)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphorylamino)propionic acid isopropyl ester 

Relevant academic research and scientific papers

The protecting-group free selective 3′-functionalization of nucleosides

The direct and chemoselective 3′-phosphoramidation, phosphorylation and acylation of nucleosides are described. Upon the discovery of a novel 3′-phosphorylamidation of therapeutic nucleoside analogues with DBU, we explored the mechanism of this rare selectivity through a combination of NMR spectroscopy and computational studies. The NMR and computational findings allowed us to develop a predictive computational model that accurately assesses the potential for 3′-functionalization for a broad range of nucleosides and nucleoside mimetics. The synthetic utility of this model was exemplified by demonstration on a broad scope of nucleosides and electrophiles yielding targets that were previously only accessible via a protection/deprotection sequence or an enzymatic approach.

PROCESS FOR MAKING PHOSPHORUS-CONTAINING NUCLEOSIDE PRODRUG COMPOUNDS

The present invention is directed to processes for making Compounds of Formula (IV): (IV) and salts thereof, wherein B, X, R1, R2, R3 and R4 are defined herein.

A high-purity rope fluorine cloth Wei compound and the preparation method of the substance

The invention belongs to the technical field of medicine, and provides a method for preparing high-purity sofosbuvir, which comprises the following steps: carrying out deprotection on the accessible raw material SF-2 by using MeONa to generate a key intermediate SF-1, connecting with the side chain of phosphate, and treating to obtain the high-purity target product sofosbuvir, in which the impurity SF-P content is extremely low. The MeONa is creatively used as the deprotection reaction reagent, and the strongly-acidic resin is used for removing alkali in the after treatment, thereby simplifying the production technique and obtaining the intermediate key intermediate SF-1 with higher purity and yield. In the sofosbuvir preparation technique, the new after-treatment method is adopted to obtain the high-purity sofosbuvir API.